F. Stephen Hodi
Member of Clinical Advisory BoardDr. F. Stephen Hodi, Jr. also known as Steve, MD, is SAB Member of Solu Therapeutics, Inc. and Corner Therapeutics, Inc. Dr. Hodi is Member of Scientific Advisory Council of Cancer Research Institute, Inc. He serves as Member of Scientific & Clinical Advisory Board at CATALYM GmbH since August 2026. Dr. Hodi MD is Scientific Advisor of Apricity Health, LLC. He served as Member of Scientific Advisory Board at Surface Oncology, Inc. and Torque Therapeutics Inc. Dr. Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center and Professor of Medicine at Harvard Medical School. He is Member of Scientific Advisory Board of Akamis Bio Limited (formerly known as PsiOxus Therapeutics Limited). He served as Member of Scientific Advisory Board at Compass Therapeutics, Inc since October 2019 until 2022 and serves as its Member of Clinical Advisory Board since 2022. Dr. Hodi was Member of Scientific Advisory Board at Checkpoint Therapeutics, Inc since March 2021 until May 30, 2025. Dr. Hodi is an internationally recognized leader in the development of immune therapy and melanoma therapeutics and is especially renowned for the clinical development of checkpoint inhibitors. Dr. Hodi has been a Member of the Scientific Advisory Board of Deciphera Pharmaceuticals, LLC since June 23, 2015; Aduro BioTech, Inc. since January 26, 2017; Infinity Pharmaceuticals, Inc. since March 2018. He is the Sharon Crowley Martin Chair in Melanoma at Dana-Farber Cancer Institute. Dr. Hodi is a Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center. He is a founding Member of the Society for Melanoma Research. Dr. Hodi is Member of International Society for the Biological Therapy of Cancer. Dr. Hodi is a Member of the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group Melanoma and the Society for Immunotherapy of Cancer and the American Association for Cancer Research. He serves as Member of Scientific Advisory Board at 7 Hills Pharma LLC since September 2021. He served as Chairman of the Clinical Advisory Board at Bicara Therapeutics Inc until June 2024 and served as its Director. He is internationally known for his work leading to FDA approval of ipilimumab, a checkpoint inhibitor used to treat melanoma. He led the first human trial and later the Phase 3 registration trial for ipilimumab. More recently, he has focused on clinical development of PD-1 and PD-L1 checkpoint inhibitors and led groundbreaking trials that combined checkpoint blockade drugs with other anti-angiogenesis agents. His work has led to improved treatments for lung and kidney cancer as well as melanoma. He is a Professor of Medicine at Harvard Medical School and was its Assistant Professor of Medicine. His research focuses on gene therapy, the development of immune therapies and first into human studies for malignant melanoma. He is a Principal investigator at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School. Dr. Hodi received his MD degree from Weill Medical College of Cornell University in 1992. He competed his postdoctoral training in Internal Medicine at the Hospital of the University of Pennsylvania and Medical Oncology training at Dana-Farber Cancer Institute and Medical Oncology training at Dana-Farber cancer Institute where he joined the faculty in 1995.
Positions
- Company NameCompass Therapeutics, Inc.Stock CodeCMPXPositionMember of Clinical Advisory BoardColleagues
- TJThomas J. SchuetzCEO & Vice Chairman
- CLCarl Lee GordonIndependent Chairman
- BSBarry ShinChief Financial Officer
- JEJonathan E. AndermanSenior VP, General Counsel & Corporate Secretary
- NLNeil L. LernerSenior VP & Chief Accounting Officer
- BGBing GongChief Scientific Officer
- PJPhilip J. FerneauIndependent Director
- RSRichard S. LindahlIndependent Director
